



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 607 054 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
20.11.2002 Bulletin 2002/47

(51) Int Cl.7: **C12N 15/12**, C12N 15/62,  
C12N 15/85, C07K 14/52,  
C07K 16/24, C12Q 1/68,  
A61K 38/19

(21) Application number: **94300267.5**

(22) Date of filing: **14.01.1994**

(54) **Novel chemokine produced by hematopoietic cells and DNA encoding said chemokine**

Neues Chemokine von hematopoietischen Zellen produziert und die dafür kodierende DNA

Nouvelle chemokine produit par des cellules hématopoïétiques et ADN codant pour celle-ci

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE**

(30) Priority: **14.01.1993 JP 2209893**

(43) Date of publication of application:  
**20.07.1994 Bulletin 1994/29**

(60) Divisional application:  
**02008698.9 / 1 243 650**

(73) Proprietors:  
• Honjo, Tasuku  
Kita-Shirakawa, Sakyo-ku, Kyoto (JP)  
• ONO PHARMACEUTICAL CO., LTD.  
Chuo-ku Osaka 541 (JP)

(72) Inventors:  
• Honjo, Tasuku Kanyu-chi  
Sakyo-ku Kyoto (JP)  
• Tashiro, Kei  
Kyoto-shi Kyoto (JP)  
• Tade, Hideaki c/o Minase Research Institute  
Shimamoto-cho Mishima-gun Osaka (JP)

(74) Representative: **Bentham, Stephen et al**  
**J.A. KEMP & CO.**  
**14 South Square**  
**Gray's Inn**  
**London WC1R 5JJ (GB)**

(56) References cited:  
**EP-A- 0 244 042 WO-A-92/18521**  
**DE-A- 3 901 681**

- **NUCL. ACIDS RES.**, vol.19, no.25, December 1991, IRL PRESS, OXFORD, ENGLAND; pages 7097 - 7104 E. HARA ET AL. 'Subtractive cDNA cloning using oligo(dT)30-latex and PCR: isolation of cDNA clones specific to undifferentiated human embryonal carcinoma cells'
- **SCIENCE**, vol.261, 30 July 1993, AAAS, WASHINGTON, DC, US; pages 600 - 603 K. TASHIRO ET AL. 'Signal sequence trap: A cloning strategy for secreted proteins and type I membrane proteins'
- **PROC. NATL. ACAD SCI.**, vol.91, no.6, 15 April 1994, NATL. ACAD SCI., WASHINGTON, DC, US; pages 2305 - 2309 T. NAGASAWA ET AL. 'Molecular cloning and structure of a pre-B-cell growth-stimulating factor'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 0 607 054 B1**

## Description

[0001] This invention relates to a novel polypeptide and a DNA coding for the same. More particularly, it relates to a novel polypeptide produced by a specific stroma cell line and a DNA coding for said polypeptide.

[0002] In order to obtain specific polypeptides (for example, proliferation and/or differentiation factors) or a DNA coding for the same, there have been generally employed methods comprising confirming the target biological activity in a tissue or a cell culture medium and then cloning of a gene through the isolation and purification of a polypeptide and further methods comprising expression-cloning of a gene with the guidance of the biological activity.

[0003] However, it is frequently observed that a gene, which has been cloned with the guidance of a certain activity, codes for a known polypeptide since many physiologically active polypeptides occurring *in vivo* have various biological activities. Further, most intravital physiologically active polypeptides are secreted only in a trace amount, which makes the isolation and purification thereof and the confirmation of biological activity difficult.

[0004] Recent rapid developments in techniques for constructing cDNAs and sequencing techniques have made it possible to quickly sequence a large amount of cDNAs. By utilising these techniques, a process, which comprises constructing cDNA libraries from various cells and tissues, cloning cDNAs at random, identifying the nucleotide sequences thereof, expressing the corresponding polypeptide and then analyzing its physiological functions, is now in use. Although this process is advantageous in that a gene can be cloned and information on its nucleotide sequence can be obtained without any biochemical or genetic analysis, the target gene can often only be identified by chance.

[0005] The present inventors have studied the cloning of genes for proliferation and differentiation factors in hematopoietic and immune systems. They have paid attention to the fact that most secretory proteins such as proliferation and/or differentiation factors (for example various cytokines) and membrane proteins such as receptors thereof (hereinafter these proteins will be referred to generally as secretory proteins and the like) have sequences called signal peptides in the N-termini. Extensive studies have been conducted to provide a process for efficiently and selectively cloning genes coding for signal peptides. As a result, a process has now been devised whereby an N-terminal fragment can be efficiently amplified and the existence of a signal peptide can be easily examined.

[0006] In accordance with this process, cDNAs with a high probability of containing a signal peptide are ligated at both their ends to linkers containing restriction enzyme sites which are different from each other. These fragments are rapidly produced in a large amount by the polymerase chain reaction (PCR) method so as to elevate the content of the fragments with a high probability of containing a signal peptide. Next, the above-mentioned fragment is introduced into an expression vector containing DNA coding for a known secretory protein or the like but lacking DNA encoding the corresponding signal peptide. Many secretory proteins and the like are secreted or expressed on cell membrane even if the signal peptide has been substituted by a signal peptide of another protein. Therefore, if the known secretory protein or the like is expressed on cell membrane or outside the cells, this confirms that a cDNA fragment corresponding to a signal peptide has been introduced into the expression vector. Thus the inventors have devised a convenient method for detection of the insertion of cDNA encoding a signal peptide.

[0007] The polymerase chain reaction is known as a method for amplifying specific DNA fragments in a large amount. It is also known that many secretory proteins and the like can be expressed even if the signal peptide thereof is substituted by that of another secretory protein or the like. However, it is believed that there has been no suggestion that these techniques be used as the inventors have been done to provide a process for selectively cloning a signal peptide.

[0008] It is known that hematopoietic cells secrete various proliferation and/or differentiation factors exemplified by interleukin. Using the process they have devised, the inventors have sought a novel factor (polypeptide) produced by hematopoietic cells. As a result, a novel polypeptide and DNA coding for the same have been identified.

[0009] Computer searches to identify polypeptides having sequences identical or highly homologous with that of the polypeptide of the present invention and the DNAs coding for the same have not identified any such sequences. Thus, the polypeptide of the present invention and the DNA coding for the same are believed to be novel. Further, homology analysis has revealed that the polypeptide of the present invention is a member of the chemokine family as it has a pattern of Cys-X-Cys (X is optional amino acid).

[0010] Accordingly, the present invention provides a polypeptide in substantially purified form having the amino acid shown in SEQ ID NO:1, the amino acid sequence of residues 1 to 70 shown in SEQ ID NO:1 or an amino acid sequence having at least 90% homology with the amino acid sequence shown in SEQ ID NO:1 over its entire length or with the amino acid sequence of residues 1 to 70 shown in SEQ ID NO:1. DNA encoding such a polypeptide is also provided. The polypeptide having the sequence shown in SEQ ID NO:1 has been identified using the process devised by the inventors.

[0011] The invention further provides:

- a replication and an expression vector comprising DNA of the invention;
- a host cell transformed or transfected with a vector of the invention;
- a method of producing a polypeptide which method comprises culturing host cells of the invention under conditions

- effective to express a polypeptide of the invention;
- a monoclonal or polyclonal antibody to a polypeptide of the invention; and
- a pharmaceutical composition containing a polypeptide or antibody of the invention in association with a pharmaceutically acceptable diluent or carrier.

Fig. 1 is a conceptional view of the process for constructing a cDNA library according to the process devised by the inventors.

Fig. 2 is a flow chart for the construction of a plasmid vector pcDL-SR $\alpha$ .

Fig. 3 is a conceptional view of the process for constructing an EcoRI-SacI fragment of hG-CSF.

Fig. 4 is a conceptional view of the process for constructing an SacI-KpnI fragment of hTac cDNA.

Fig. 5 is a flow chart for the construction of pSGT and pSRT.

Fig. 6 is a conceptional view of the process for constructing an EcoRI-SacI fragment of hRAR $\alpha$ .

Fig. 7 is an FACS histogram showing the expression of a fusion protein hG-CSF-hTac on membrane.

Fig. 8 is an FACS histogram showing the expression of a fusion protein hRAR-hTac on membrane.

Fig. 9 is a conceptional view of the first half of the process for constructing the cDNA library of the Example.

Fig. 10 is a conceptional view of the second half of the process or constructing the cDNA library of the Example.

Fig. 11 is a hydrophobicity profile of (a part of) the polypeptide according to the present invention.

**[0012]** The present invention thus relates to a novel polypeptide which has been identified using the process devised by the present inventors to construct a cDNA library. In particular, it relates to:

- (1) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO. 1;
- (2) a DNA coding for the polypeptide (1);
- (3) a DNA having a nucleotide sequence represented by SEQ ID No. 4; and
- (4) a DNA having a nucleotide sequence represented by SEQ ID NO. 3.

**[0013]** A polypeptide of Seq. ID No. 1 in substantially purified form will generally comprise the polypeptide in a preparation in which more than 90%, eg. 95%, 98% or 99% of the polypeptide in the preparation is that of the Seq. ID No. 1.

**[0014]** A polypeptide homologue of the Seq. ID No. 1 will be at least 90% and more preferably at least 95% homologous to the polypeptide of Seq. ID No. 1 over a region of at least 30, for instance 40, 60 or 100 more contiguous amino acids. Such polypeptide homologues will be referred to below as a polypeptide according to the invention.

**[0015]** Generally, fragments of Seq. ID No. 1 or its homologues will be at least 30, for example 40, 50 or 60 amino acids in length, and are also encompassed by the term "a polypeptide according to the invention" as used herein. Particular fragments of the polypeptides of the invention are fragments which include amino acid residues numbered 1-70 in Seq ID No. 1 or a homologue thereof.

**[0016]** A DNA capable of selectively hybridizing to the DNA of Seq. ID No. 3 or 4 will be generally at least 90% and more preferably at least 95% homologous to the DNA of Seq. ID No. 3 or 4 over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 or more contiguous nucleotides. Such DNA will be encompassed by the term "DNA according to the invention".

**[0017]** Particular DNA capable of selectively hybridising to the DNA of SEQ ID No. 3 or 4 is the nucleotide residues numbered 139-348 in SEQ ID No. 1 or a fragment thereof.

**[0018]** DNA according to the invention may be used to produce a primer, eg. a PCR primer, a probe eg. labelled by conventional means using radioactive or nonradioactive labels, or the DNA may be cloned into a vector. Such primers, probes and other fragments of the DNA of Seq. ID No. 3 or 4 will be at least 15, preferably at least 20, for example 25, 30 or 40 nucleotides in length.

**[0019]** DNA according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art.

**[0020]** A further embodiment of the invention provides replication and expression vectors comprising DNA according to the invention. The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said DNA and optionally a regulator of the promoter. The vector may contain one or more selectable marker genes, for example an ampicillin resistance gene. The vector may be used *in vitro*, for example for the production of RNA corresponding to the DNA, or used to transform a host cell.

**[0021]** A further embodiment of the invention provides host cells transformed or transfected with the vectors for the replication and expression of DNA according to the invention, including the DNA Seq. ID No.3 or 4 or the open reading frame thereof. The cells will be chosen to be compatible with the vector and may for example be bacterial, yeast, insect or mammalian.

**[0022]** DNA according to the invention may also be inserted into the vectors described above in an antisense orientation in order to provide for the production of antisense RNA (DNA). Antisense RNA (DNA) may also be produced by

synthetic means. Such antisense RNA (DNA) may be used in a method of controlling the levels of a polypeptide of the invention in a cell.

[0023] A further embodiment of the invention provides a method of producing a polypeptide which comprises culturing host cells of the present invention under conditions effective to express a polypeptide of the invention. Preferably, in addition, such a method is carried out under conditions in which the polypeptide of the invention is expressed and then secreted from the host cells.

[0024] The invention also provides monoclonal or polyclonal antibodies to a polypeptide according to the invention. The invention further provides a process for the production of monoclonal or polyclonal antibodies to the polypeptides of the invention. Monoclonal antibodies may be prepared by conventional hybridoma technology using a polypeptide of the invention or a fragment thereof, as an immunogen. Polyclonal antibodies may also be prepared by conventional means which comprise inoculating a host animal, for example a rat or a rabbit, with a polypeptide of the invention and recovering immune serum.

[0025] The present invention also provides pharmaceutical compositions containing a polypeptide of the invention, or an antibody thereof, in association with a pharmaceutically acceptable diluent or carrier.

[0026] The invention also provides a polypeptide according to the invention or an antibody for use in a method of therapy or diagnosis on a human or animal body.

[0027] The polypeptides of the present invention include not only those having the amino acid sequence represented by the SEQ ID No. 1 but also those with partial deletion thereof (for example, a polypeptide consisting of the mature protein part alone, or consisting of a part of the mature protein essentially required for the expression of the biological activity), those with partial replacement by other amino acid(s) (for example, a polypeptide some of amino acids are replaced by those having similar properties) and those with partial addition or insertion of amino acid(s).

[0028] It is well known that there are up to six different codons which may code for a single amino acid (for example, one type of codon for Met while six types of codon for Leu). Accordingly, the nucleotide sequence of the DNA can be changed without altering the amino acid sequence of the polypeptide.

[0029] The DNA as specified in (2) includes all nucleotide sequences coding for the polypeptide represented by Seq. ID NO. 1. Changes in the nucleotide sequence sometimes bring about an increase in the polypeptide productivity.

[0030] The DNA as specified in (3) is an embodiment of the DNA as specified in (2) and represents a natural sequence.

[0031] The DNA as specified in (4) represents a sequence wherein a natural non-translational region is added to the DNA as specified in (3).

[0032] A signal peptide is a highly hydrophobic region located immediately downstream of the translation initiation amino acid Met. It is assumed that the signal peptide in the polypeptide of the present invention resides in a region ranging from Met at the 1-position to Ser at the 19-position in the amino acid sequence represented by Seq. ID No. 1. The region essentially responsible for the expression of the biological activity corresponds to the part of the amino acid sequence of the Seq. ID No. 1 lacking of the signal peptide, i.e., the mature protein part. Thus the signal peptide never relates to the activity.

[0033] Once the nucleotide sequences represented by Seq. ID No. 3 and No. 4 are determined, the DNA of the present invention can be chemically synthesized. Alternatively, the DNA of the present invention can be obtained by chemically synthesizing fragments of said nucleotide sequence and hybridizing with the use of the fragments as a probe. Further, the target DNA can be produced in a desired amount by introducing a vector DNA containing said DNA into an appropriate host and then incubating the host.

[0034] Examples of methods for obtaining the polypeptide of the present invention include:

- (1) isolation and purification from vital tissues or cultured cells;
- (2) chemical synthesis of peptides; and
- (3) production with the use of gene recombination techniques. From an industrial viewpoint, the method described in (3) is preferable.

[0035] Examples of the expression system (host-vector system) for producing the polypeptide by using gene recombination techniques include those of bacteria, yeasts, insect cells and mammalian cells.

[0036] In order to express in *E. coli*, for example, an initiator codon (ATG) is added to the 5'-end of the DNA coding for the mature protein region. The DNA thus obtained is then ligated to the downstream of an appropriate promoter (for example, trp promoter, lac promoter,  $\lambda$ p<sub>L</sub> promoter, T7 promoter, etc.) and inserted into a vector capable of functioning in *E. coli* (for example, pBR322, pUC18, pUC19, etc.), thus constructing an expression vector. Next, an *E. coli* strain (for example, *E. coli* DH1, *E. coli* JM109, *E. coli* HB101, etc.) transformed with this expression vector is incubated in an appropriate medium. Thus the target polypeptide can be obtained from the incubated cells. Alternately, a bacterial signal peptide (for example, a signal peptide of pelB) may be used and thus the polypeptide can be secreted into the periplasm. Furthermore, a fusion protein together with other polypeptide can be produced.

[0037] Expression in mammalian cells can be effected, for example, in the following manner. Namely, a DNA coding for the nucleotide sequence represented by Seq. ID No. 3 is inserted into the downstream of an appropriate promoter (for example, SV40 promoter, LTR promoter, metallothionein promoter, etc.) in an appropriate vector (for example, retrovirus vector, papilloma virus vector, vaccinia virus vector, SV40-series vector, etc.), thus constructing an expression vector. Next, appropriate mammalian cells (for example, monkey COS-7 cells, Chinese hamster CHO cells, mouse L cells, etc.) are transformed with the expression vector obtained above and the transformant is incubated in an appropriate medium. Thus the target polypeptide can be secreted into the culture medium. The polypeptide thus obtained can be isolated and purified by conventional biochemical methods.

[0038] The novel polypeptide which is the subject of the present invention is produced and secreted from a stroma cell line. Therefore, the polypeptide has biological activities relating to the survival and proliferation of hematopoietic stem cells and the proliferation and differentiation of B cells and myeloid cells, and chemoattractant activity of neutrophil. Accordingly, the polypeptide of the present invention per se is usable as an agent for preventing or treating, for example, anemia or leukopenia, infections, etc.

[0039] In addition, the above-mentioned polypeptide existing in vivo can be assayed by using a polyclonal antibody or a monoclonal antibody for said polypeptide, which is applicable to studies on the relationship between said polypeptide and diseases or to the diagnosis of diseases and the like. The polyclonal antibody and the monoclonal antibody can be prepared by a conventional method with the use of said polypeptide or a fragment thereof as an antigen.

[0040] The DNA according to the present invention serves as an important and essential template in the production of the polypeptide of the present invention which is expected to be highly useful. Further, the DNA of the present invention is applicable to the diagnosis and treatment of hereditary diseases, i.e., gene therapy, and therapy with ceasing the expression of the polypeptide by using antisense DNA (RNA). Furthermore, a genomic DNA can be isolated by using the DNA of the present invention as a probe. Similarly, a human gene for a related polypeptide being highly homologous with the DNA of the present invention and a gene of an organism other than human for a polypeptide being high homologous with the polypeptide of the present invention can be isolated.

#### Examples


[0041] The following Examples and Reference Example are illustrated, but not limit the present invention.

#### Reference Example 1

[0042] Construction and expression of plasmid pcDL-SR $\alpha$ -h-G-CSF-hTac (pSGT) and plasmid pcDL-SR $\alpha$ -hRAR $\alpha$ -hTac (pSRT)

[0043] A plasmid, wherein a cDNA coding for a fusion protein of hG-CSF (human granulocyte colony stimulating factor, a typical example of a protein having a signal peptide) or hRAR $\alpha$  (human retinoic acid receptor  $\alpha$ , a typical example of a protein having no signal peptide), with hTac (human IL-2 receptor  $\alpha$ , used as a reporter gene) was integrated into an eucaryotic cell expression plasmid vector pcDL-SR $\alpha$  having an SR $\alpha$  promoter [described in Mol. Cell. Biol., 8, 466 (1988), provided by Dr. Yutaka Takebe, National Institute of Health], was constructed. After transformation, the expression of the reporter protein on the membrane was examined.


(1) By employing a plasmid pSP72-hG-CSF, wherein hG-CSF cDNA had been integrated into the EcoRI site of a plasmid pSP72 (purchased from Promega), as a template and using an SP6 promoter primer (purchased from Takara Shuzo Co., Ltd.) and an hG-CSF specific primer having an SacI site added thereto (SEQ ID No. 5):



PCR was performed 25 cycles (at 95 °C for one minute, at 48 °C for two minutes and at 72 °C for two minutes). The amplified DNA fragment was digested with SacI-EcoRI and once subcloned into a plasmid pBlue script SK(+) (pBS). After digesting with SacI-EcoRI again, an EcoRI-SacI fragment of hG-CSF was obtained. On the other hand, a plasmid pBS-hTac, wherein hTac cDNA had been integrated into the HindIII site of pBS, was digested with SacI-KpnI to thereby give an SacI-KpnI fragment of hTac cDNA with the deletion of the signal sequence. These fragments were integrated into the EcoRI-KpnI site of pcDL-SR $\alpha$  with the deletion of stuffer (Fig. 2) to thereby give

a plasmid pcDL-SR $\alpha$ -hG-CSF-hTac (pSGT) (Figs. 3, 4 and 5).

Next, by employing a plasmid pGEM3-hRAR $\alpha$ , wherein hRAR $\alpha$  cDNA had been integrated into the EcoRI site of a plasmid pGEM3, as a template and using an SP6 promoter primer and an hRAR $\alpha$  specific primer having an SacI site added thereto (SEQ ID No. 6):



PCR was performed. Subsequently, the procedure employed in the above-mentioned case of G-CSF was repeated to thereby give a plasmid pcDL-SR $\alpha$ -hRAR $\alpha$ -hTac (pSRT) (Figs. 6, 4 and 5).


(2) The pSGT or pSRT obtained in the above (1) was transfected into COS-7 cells by the DEAE-dextran method [described in detail in Current Protocol in Molecular Biology, chapter 9.2.1.]. After 48 hours, the cells were harvested from a dish and incubated together with mouse anti-Tac IgG antibody for 20 minutes on ice. After eliminating free antibodies, the mixture was incubated together with goat anti-mouse IgG antibody labeled with fluorescein isothiocyanate (FITC) for 20 minutes on ice. After eliminating free antibodies again, the expression of a fusion protein G-CSF-Tac or RAR $\alpha$ -Tac on the membrane was examined with a fluorescence activated cell sorter (Model FACS Can, manufactured by BECTON DICKINSON, hereinafter referred to simply as FACS). Figs. 7 and 8 show the results of the judgement.

**[0044]** As shown in Fig. 7, G-CSF-Tac was expressed on the membrane as well as Tac. As shown in Fig. 8, on the other hand, RAR $\alpha$ -Tac was not detected on the membrane but remained within the cells.

#### Example 1

Construction of cDNA library having selectivity for signal peptides (Figs. 9 and 10)

**[0045]** Total RNA was extracted from a mouse stroma cell line ST2 [cells supporting the survival and proliferation of hematopoietic stem cells and the proliferation and differentiation of B cells and myeloid cells; refer to EMBO J., 7, 1337 (1988)] by the acid guanidine-phenol-chloroform (AGPC) method [described in detail in "Saibo Kogaku Jikken Protokoru (Protocol in Cellular Engineering Experiments)", published by Shujun-sha, 28 - 31]. Then poly A-RNA was purified by using oligo (dT)-latex (Oligotex-dT30®, marketed from Takara Shuzo Co., Ltd.). By using a random hexamer as a primer, a single-stranded cDNA was synthesized with reverse transcriptase and dT was added to the 3'-end thereof with the use of terminal deoxytransferase. A 17 mer dA ligated to a restriction enzyme site containing EcoRI (SEQ ID No. 7):



was annealed and a double-stranded cDNA was synthesized by using the same as a primer. Then the cDNA was fragmented by ultrasonication so as to give an average length of 300 bp and the cDNAs of 200 to 500 bp were fractionated by agarose gel electrophoresis. After blunting the ends with T4DNA polymerase, a lone linker containing an SacI site

5' GAGGTACAAGCTT GATATC GAGCTCGCGG 3' (SEQ ID No.8)  
 3' CATGTTTCGAA CTATAG CTCGAGCGCC 5' (SEQ ID No.9)  
                   Hind III   EcoRV    Sacl

[see Nucleic Acids Res., 18, 4293 (1990)] was ligated and cDNAs of 200 to 500 bp were fractionated again by agarose gel electrophoresis. By using a primer (NLC) containing an EcoRI site (SEQ ID No. 10):

NLC

5' GATGCGGCCCGCCTCGAGGAATTC 3'

and another primer (LLHES) containing an SacI site (SEQ ID No. 11):

LLHES

5' GAGGTACAAGCTTGATATCGAGCTCGCGG 3'

PCR was performed 25 cycles (at 94 °C for one minute, at 50 °C for two minutes and at 72 °C for two minutes). The amplified cDNA was digested with SacI and EcoRI and cDNAs of 250 to 500 bp were fractionated by agarose gel electrophoresis. The cDNA was ligated to a plasmid obtained by digesting pSRT (prepared in Reference Example 1) with SacI and EcoRI by using T4 DNA ligase. After transformation of an *E. coli* DH5α strain, a cDNA library having a selectivity for signal peptides was obtained.

## Example 2

Screening and analysis of cDNA coding for signal peptide

[0046] About 1,200 colonies in the library obtained in Example 1 were divided into 24 pools (about 50 colonies/pool). Plasmids of each pools were isolated by the miniprep method and transfected into COS-7 cells by the DEAE-dextran method. After 48 to 72 hours, cell surface-staining for Tac of the transfectant was performed in the same manner as described in Reference Example 1 and 6 positive pools were selected under a fluorescent microscope. Colonies of one pool from among the 6 positive pools were further divided and the same procedure as described above was repeated until a single clone was obtained. Thus a positive clone (pS-TT3) was obtained. Subsequently, by using two synthetic primers (SEQ ID No. 12):

5' TTTACTTCTAGGCCTGTACG 3'

(20 bases upstream from EcoRI cloning site, for sense) and (SEQ ID No. 13):

5' CCATGGCTTTGAATGTGGCG 3'

(20 bases downstream from SacI cloning site, for antisense) which were specific for the pcDL-SRα-Tac vector, the nucleotide sequence of the TT3 insert was determined. An open reading frame following the Tac cDNA with the deletion of the signal sequence in-frame was searched and converted into the deduced amino acid sequence. After performing

a hydrophobicity profile, it was confirmed that a hydrophobic region characteristic to a signal peptide was contained therein (Fig. 11). Further, the homology with data base on DNA and amino acid levels was examined. As a result, it has been found out that TT3 clone codes for an unknown protein.

### Example 3

Screening of cDNA with the full length and determination of nucleotide sequence

[0047] A cDNA library was constructed by using Super Script® Ramda System (marketed from BRL). Next, pS-TT3 was digested with SacI and EcoRI and a TT3 cDNA fragment was prepared by agarose gel electrophoresis. The library was screened by using an oligo-labeled TT3 cDNA fragment as a probe and thus a number of positive clones were obtained. Among these clones, a TT3-1-6 clone showing the longest insert was selected and an Sall-NotI fragment excised from a  $\lambda$ gt22A vector was subcloned into pBS to thereby give a plasmid pBS-TT316. By using a T7 primer, the nucleotide sequence of 300 bp in the 5'-terminal of TT3-1-6 cDNA was determined. Thus it was confirmed that the sequence identical with TT3 of the probe existed in the most 5'-end of TT3-1-6.

[0048] Next, a number of pBS-TT316 variant plasmids lacking of the 5'-end or the 3'-end of TT3-1-6 cDNA were constructed by using an ExoIII/Mung Bean Deletion Kit (manufactured by Stratagene). By using these variant plasmids, the nucleotide sequence of the full length cDNA was determined (SEQ ID No. 3). From the full length cDNA sequence data, an open reading frame was determined and further translated into an amino acid sequence. Thus the sequence represented by Seq. ID No. 1 was obtained. The amino acid sequence at the 30- to 40-positions in the N-terminal of the amino acid sequence thus obtained were compared with known signal peptides. Thus the signal peptide part of this polypeptide was deduced to thereby give the sequence represented by Seq. ID No. 1.

### SEQUENCE LISTING

#### [0049]

#### (1) GENERAL INFORMATION:

##### (i) APPLICANT:

(A) NAME: HONJO, TASUKU  
(B) STREET: KANYU-CHI, OIWAKE-CHO, KITA-SHIRAKAWA, SAKYO-KU  
(C) CITY: KYOTO  
(E) COUNTRY: JAPAN  
(F) POSTAL CODE (ZIP): none

(A) NAME: ONO PHARMACEUTICAL Co. LTD  
(B) STREET: 1-5 DOSHOMACHI 2-CHOME, CHUOKU  
(C) CITY: OSAKA  
(E) COUNTRY: JAPAN  
(F) POSTAL CODE (ZIP): 541

(ii) TITLE OF INVENTION: PROCESS FOR CONSTRUCTING A cDNA LIBRARY AND A NOVEL POLYPEPTIDE AND DNA ENCODING THE SAME

(iii) NUMBER OF SEQUENCES: 13

##### (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0. Version #1.25 (EPO)

(v) CURRENT APPLICATION DATA: APPLICATION NUMBER: EP 94300267.5

#### (2) INFORMATION FOR SEQ ID NO: 1:



(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1797 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 82..138

(ix) FEATURE:

(A) NAME/KEY: mat\_peptide  
(B) LOCATION: 139..348

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GACCACTTTC CCTCTCGGTC CACCTCGGTG TCCTCTTGCT GTCCAGCTCT GCAGCCTCCG 60  
GCGCGCCCTC CCGCCCACGC C ATG GAC GCC AAG GTC GTC GCC GTG CTG GCC 111

**EP 0 607 054 B1**

	Met Asp Ala Lys Val Val Ala Val Leu Ala	
	-15 -10	
5	CTG GTG CTG GCC GCG CTC TGC ATC AGT GAC GGT AAA CCA GTC AGC CTG Leu Val Leu Ala Ala Leu Cys Ile Ser Asp Gly Lys Pro Val Ser Leu	159
	-5                        1                    5	
10	AGC TAC CGA TGC CCC TGC CGG TTC TTC GAG AGC CAC ATC GCC AGA GCC Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser His Ile Ala Arg Ala	207
	10                                   15                      20	
15	AAC GTC AAG CAT CTG AAA ATC CTC AAC ACT CCA AAC TGT GCC CTT CAG Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro Asn Cys Ala Leu Gln	255
	25                                   30                      35	
20	ATT GTT GCA CGG CTG AAG AAC AAC AAC AGA CAA GTG TGC ATT GAC CCG Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln Val Cys Ile Asp Pro	303
	40                                   45                      50                      55	
25	AAA TTA AAG TGG ATC CAA GAG TAC CTG GAG AAA GCT TTA AAC AAG Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn Lys	348
	60                             65                      70	
30	TAAGCACAAAC AGCCCAAAGG ACTTTCAGT AGACCCCCGA GGAAGGCTGA CATCCGTGGG	408
35	AGATGCAAGG GCAGTGGTG GGAGGAGGGC CTGAACCCTG GCCAGGATGG CCGGCCGGAC	468
40	AGCACTGACT GGGGTCATGC TAAGGTTTGC CAGCATAAAG AACTCCGCC ATAGCATATG	528
45	GTACGATATT GCAGCTTATA TTCATCCCTG CCCTCGCCCG TGACAATGG AGCTTTTATA	588
50	ACTGGGGTTT TTCTAAGGAA TTGTATTACC CTAACCAGTT AGCTTCATCC CCATTCTCCT	648
55	CATCCTCATC TTCATTTTAA AAAGCAGTGA TTA CTCTCAAG GGCTGTATTC AGTTTGCTTT	708
60	GGAGCTTCTC TTTGCCCTGG GGCCTCTGGG CACAGTTATA GACGGTGGCT TTGCAGGGAG	768
65	CCCTAGAGAG AAACCTTCCA CCAGAGCAGA GTCCGAGGAA CGCTGCAGGG CTTGTCCTGC	828
70	AGGGGGCGCT CCTCGACAGA TGCTTGTGCC TGAGTCAACA CAAGATCCGG CAGAGGGAGG	888
75	CTCCTTTATC CAGTTCAGTG CCAGGTCGG GAAGCTTCCT TTAGAAGTGA TCCCTGAAGC	948
80	TGTGCTCAGA GACCCTTTCC TAGCCGTTCC TGCTCTCTGC TTGCCTCAA ACGCATGCTT	1008
85	CATCTGACTT CCGCTTCTCA CCTCTGTAGC CTGACGGACC AATGCTGCAA TGGAGGGGAG	1068
90	GAGAGTGATG TGGGGTGCCC CCTCCCTCTC TTCCCTTTC TTTCTCTCA CTTGGGCCCT	1128
95	TTGTGAGATT TTTCTTTGGC CTCCTGTAGA ATGGAGCCAG ACCATCCTGG ATAATGTGAG	1188
100	AACATGCCTA GATTTACCCA CAAAAACAA GTCTGAGAAT TAATCATAAA CGGAAGTTTA	1248
105	AATGAGGATT TGGACCTTGG TAATTGTCCC TGAGTCCTAT ATATTCAAC AGTGGCTCTA	1308
110	TGGGCTCTGA TCGAATATCA GTGATGAAAA TAATAATAAT AATAATAATA ACGAATAAGC	1368
115	CAGAATCTTG CCATGAAGCC ACAGTGGGGA TTCTGGGTTT CAATCAGAAA TGGAGACAAG	1428

5 ATAAACTTG CATACATTCT TATGATCACA GACGGCCCTG GTGGTTTTTG GTAAC TATT 1488  
 ACAAGGCATT TTTTACATA TATTTTGTG CACTTTTAT GTTCTTTGG AAGACAAATG 1548  
 TATTCAGAA TATATTTGTA GTCAATTCAT ATATTTGAAG TGGAGCCATA GTAATGCCAG 1608  
 TAGATATCTC TATGATCTTG AGCTACTGGC AACTTGTAAG GAAATATATA TGACATATAA 1668  
 10 ATGTATTGTA GCTTCCGGT GTCAGCCACG GTGTATTTT CCACTTGGAA TGAAATTGTA 1728  
 TCAACTGTGA CATTATATGC ACTAGCAATA AAATGCTAAT TGTTCATGC TGTAACAAAAA 1788  
 15 AAAAAAAA 1797

## (2) INFORMATION FOR SEQ ID NO: 2:

## 20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 89 amino acids

(B) TYPE: amino acid

25 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

30

Met Asp Ala Lys Val Val Ala Val Leu Ala Leu Val Leu Ala Ala Leu  
 1 5 10 15

35

Cys Ile Ser Asp Gly Lys Pro Val Ser Leu Ser Tyr Arg Cys Pro Cys  
 20 25 30

Arg Phe Phe Glu Ser His Ile Ala Arg Ala Asn Val Lys His Leu Lys  
 35 40 45

40

Ile Leu Asn Thr Pro Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys  
 50 55 60

Asn Asn Asn Arg Gln Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln  
 65 70 75 80

45

Glu Tyr Leu Glu Lys Ala Leu Asn Lys  
 85

## (2) INFORMATION FOR SEQ ID NO: 3:

50

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1797 base pairs

(B) TYPE: nucleic acid

55 (C) STRANDEDNESS: double

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

**EP 0 607 054 B1**

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GACCACTTTC CCTCTCGGTC CACCTCGGTG' TCCTCTTGCT GTCCAGCTCT GCAGCCTCCG 60

5

10

15

20

25

30

35

40

45

50

55

	GC GCGCCCTC CCGCCACGC CATGGACGCC AAGGTCGTCG CCGTGCTGGC CCTGGTGCTG	120
5	GCCGCGCTCT GCATCAGTGA CGGTAAACCA GTCAGCCTGA GCTACCGATG CCCCTGCCGG	180
	TTCTTCGAGA GCCACATCGC CAGAGCCAAC GTCAAGCATC TGAATCCT CAACACTCCA	240
	AACTGTGCCC TTCAGATTGT TGCACGGCTG AAGAACAACA ACAGACAAGT GTGCATTGAC	300
10	CCGAAATTAA AGTGGATCCA AGAGTACCTG GAGAAAGCTT TAAACAAGTA AGCACAACAG	360
	CCCAAAGGAC TTTCCAGTAG ACCCCCGAGG AAGGCTGACA TCCGTGGGAG ATGCAAGGGC	420
	AGTGGTGGGG AGGAGGGCCT GAACCTGGC CAGGATGGCC GGCGGGACAG CACTGACTGG	480
15	GGTCATGCTA AGGTTTGCCA GCATAAGAC ACTCCGCCAT AGCATATGGT ACGATATTGC	540
	AGCTTATATT CATCCCTGCC CTCGCCGTG CACAATGGAG CTTTTATAAC TGGGGTTTTT	600
20	CTAAGGAATT GTATTACCCT AACCAGTTAG CTTTCATCCC ATTCTCCTCA TCCTCATCTT	660
	CATTTTAAAA AGCAGTGATT ACTTCAAGGG CTGTATTCAG TTTGCTTTGG AGCTTCTCTT	720
	TGCCCTGGGG CCTCTGGGCA CAGTTATAGA CGGTGGCTTT GCAGGGAGCC CTAGAGAGAA	780
25	ACCTTCACC AGAGCAGAGT CCGAGGAACG CTGCAGGGCT TGTCTGCAG GGGGCGCTCC	840
	TCGACAGATG CCTTGTCTG AGTCAACACA AGATCCGGCA GAGGGAGGCT CCTTTATCCA	900
	GTTCAGTGCC AGGGTCGGGA AGCTTCCTTT AGAAGTGATC CCTGAAGCTG TGCTCAGAGA	960
30	CCCTTTCCTA GCCGTTCTG CTCTCTGCTT GCCTCCAAAC GCATGCTTCA TCTGACTTCC	1020
	GCTTCTCACC TCTGTAGCCT GACGGACCAA TGCTGCAATG GAAGGGAGGA GAGTGATGTG	1080
35	GGGTGCCCCC TCCCTCTCTT CCCTTTGCTT TCCTCTCACT TGGGCCCTTT GTGAGATTTT	1140
	TCTTTGGCCT CCTGTAGAAT GGAGCCAGAC CATCCTGGAT AATGTGAGAA CATGCCTAGA	1200
	TTTACCCACA AAACACAAGT CTGAGAATTA ATCATAAACG GAAGTTTAAA TGAGGATTTG	1260
40	GACCTTGGTA ATTGTCCCTG AGTCTATAT ATTTCAACAG TGGCTCTATG GGCTCTGATC	1320
	GAATATCAGT GATGAAAATA ATAATAATAA TAATAATAAC GAATAAGCCA GAATCTTGCC	1380
	ATGAAGCCAC AGTGGGGATT CTGGGTTCCA ATCAGAAATG GAGACAAGAT AAAACTTGCA	1440
45	TACATTCTTA TGATCACAGA CGGCCCTGGT GGTTTTGGT AACTATTTAC AAGGCATTTT	1500
	TTTACATATA TTTTGTGCA CTTTTATGT TTCTTTGGAA GACAAATGTA TTTCAGAATA	1560
50	TATTTGTAGT CAATTCATAT ATTTGAAGTG GAGCCATAGT AATGCCAGTA GATATCTCTA	1620
	TGATCTTGAG CTAAGGCA CTTGTAAAGA AATATATATG ACATATAAAT GTATTGTAGC	1680
	TTTCCGGTGT CAGCCACGGT GTATTTTCC ACTTGAATG AAATTGTATC AACTGTGACA	1740
55	TTATATGCAC TAGCAATAAA ATGCTAATTG TTTCATGCTG TAAAAAAAAA AAAAAA	1797

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 267 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

ATGGACGCCA AGGTCGTCGC CGTGCTGGCC CTGGTGCTGG CCGCGCTCTG CATCAGTGAC 60  
 GGTAAACCAG TCAGCCTGAG CTACCGATGC CCCTGCCGGT TCTTCGAGAG CCACATCGCC 120  
 AGAGCCAACG TCAAGCATCT GAAAATCCTC AACACTCCAA ACTGTGCCCT TCAGATTGTT 180  
 GCACGGCTGA AGAACAACAA CAGACAAGTG TGCATTGACC CGAAATTAAA GTGGATCCAA 240  
 GAGTACCTGG AGAAAGCTTT AAACAAG 267

## (2) INFORMATION FOR SEQ ID NO: 5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GGAGATATCG AGCTCCTCGG GGTGGCACAG 30

## (2) INFORMATION FOR SEQ ID NO: 6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GGAGATATCG AGCTCAATGG TGGCTGGGGA TG 32

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 40 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

15 GATGCGGCCG CCTCGAGGAA TTCAAAAAA AAAAAAAAAA 40

(2) INFORMATION FOR SEQ ID NO: 8:

20 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

30 GAGGTACAAG CTTGATATCG AGCTCGCGG 29

35 (2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

50 CCGCGAGCTC GATATCAAGC TTGTAC 26

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- 55 (A) LENGTH: 23 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GATGCGGCCG CCTCGAGGAA TTC

23

10

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

15

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

25

GAGGTACAAG CTTGATATCG AGCTCGCGG

29

(2) INFORMATION FOR SEQ ID NO: 12:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

35

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

40

TTTACTTCTA GGCCTGTACG

20

(2) INFORMATION FOR SEQ ID NO: 13:

45

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

50

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:



CCATGGCTTT GAATGTGGCG

20

5

**Claims**

1. A polypeptide in substantially purified form having the amino acid sequence shown in SEQ ID NO. 1, the amino acid sequence of residues 1 to 70 shown in SEQ ID NO. 1 or an amino acid sequence having at least 90% homology with the amino acid sequence shown in SEQ ID NO. 1 over its entire length or with the amino acid sequence of residues 1 to 70 shown in SEQ ID NO. 1.
2. A polypeptide according to claim 1 having the amino acid sequence shown in SEQ ID NO. 1.
3. A polypeptide according to claim 1 having the amino acid sequence of residues 1 to 70 shown in SEQ ID NO. 1.
4. DNA encoding a polypeptide according to any one of the preceding claims.
5. DNA according to claim 4 having the nucleotide sequence shown in SEQ ID NO. 4.
6. DNA according to claim 4 having the nucleotide sequence shown in SEQ ID No. 3.
7. DNA according to claim 4 having the nucleotide sequence of residues 139 to 348 shown in SEQ ID NO. 1.
8. A replication and expression vector comprising DNA according to any one of claims 4 to 7.
9. A host cell transformed or transfected with a replication and expression vector according to claim 8.
10. A method of producing a polypeptide which comprises culturing host cells according to claim 10 under conditions effective to express a polypeptide according to any one of claims 1 to 3.
11. A monoclonal or polyclonal antibody to a polypeptide according to any one of claims 1 to 3.
12. A pharmaceutical composition containing a polypeptide according to any one of claims 1 to 3 or an antibody according to claim 11 in association with a pharmaceutically acceptable diluent or carrier.


**Patentansprüche**

1. Polypeptid in im wesentlichen gereinigter Form mit der Aminosäuresequenz, die in SEQ ID NO. 1 angegeben ist, mit der Aminosäuresequenz der Reste 1 bis 70, die in SEQ ID NO. 1 angegeben ist, oder mit einer Aminosäuresequenz mit mindestens 90 % Homologie mit der Aminosäuresequenz, die in SEQ ID NO. 1 angegeben ist, über deren gesamte Länge oder mit der Aminosäuresequenz der Reste 1 bis 70, die in SEQ ID NO. 1 angegeben ist.
2. Polypeptid nach Anspruch 1 mit der Aminosäuresequenz, die in SEQ ID NO. 1 angegeben ist.
3. Polypeptid nach Anspruch 1 mit der Aminosäuresequenz der Reste 1 bis 70, die in SEQ ID NO. 1 angegeben ist.
4. DNA mit Kodierung für ein Polypeptid gemäß einem der vorhergehenden Ansprüche.
5. DNA nach Anspruch 4 mit der Nucleotidsequenz, die in SEQ ID NO. 4 angegeben ist.
6. DNA nach Anspruch 4 mit der Nucleotidsequenz, die in SEQ ID NO. 3 angegeben ist.
7. DNA nach Anspruch 4 mit der Nucleotidsequenz der Reste 139 bis 348, die in SEQ ID NO. 1 angegeben ist.
8. Replikations- und Expressionsvektor, der DNA nach einem der Ansprüche 4 bis 7 umfasst.


9. Wirtszelle, die mit einem Replikations- und Expressionsvektor nach Anspruch 8 transformiert oder transfiziert wurde.
10. Verfahren zur Herstellung eines Polypeptids, das ein Kultivieren von Wirtszellen nach Anspruch 9 unter Bedingungen, die für eine Expression eines Polypeptids nach einem der Ansprüche 1 bis 3 wirksam sind, umfasst.
11. Monoklonaler oder polyklonaler Antikörper gegen ein Polypeptid nach einem der Ansprüche 1 bis 3.
12. Pharmazeutische Zusammensetzung, die ein Polypeptid nach einem der Ansprüche 1 bis 3 oder einen Antikörper nach Anspruch 11 in Verbindung mit einem pharmazeutisch akzeptablen Verdünnungsmittel oder Träger enthält.


#### Revendications

1. Polypeptide sous forme essentiellement purifiée, ayant la séquence d'acides aminés présentée dans SEQ ID N° 1, la séquence d'acides aminés des résidus 1 à 70 présentés dans SEQ ID N° 1 ou une séquence d'acides aminés ayant une homologie d'au moins 90 % avec la séquence d'acides aminés présentée dans SEQ ID N° 1 sur toute sa longueur ou avec la séquence d'acides aminés des résidus 1 à 70 présentés dans SEQ ID N° 1.
2. Polypeptide selon la revendication 1, ayant la séquence d'acides aminés présentée dans SEQ ID N° 1.
3. Polypeptide selon la revendication 1, ayant la séquence d'acides aminés des résidus 1 à 70 présentés dans SEQ ID N° 1.
4. ADN codant pour un polypeptide selon l'une quelconque des revendications précédentes.
5. ADN selon la revendication 4, ayant la séquence de nucléotides présentée dans SEQ ID N° 4.
6. ADN selon la revendication 4, ayant la séquence de nucléotides présentée dans SEQ ID N° 3.
7. ADN selon la revendication 4, ayant la séquence de nucléotides des résidus 139 à 348 présentés dans SEQ ID N° 1.
8. Vecteur de réplication et d'expression comprenant un ADN selon l'une quelconque des revendications 4 à 7.
9. Cellule hôte transformée ou transfectée avec un vecteur de réplication et d'expression selon la revendication 8.
10. Procédé de production d'un polypeptide, comprenant la culture de cellules hôtes selon la revendication 9 dans des conditions efficaces pour l'expression d'un polypeptide selon l'une quelconque des revendications 1 à 3.
11. Anticorps monoclonal ou polyclonal dirigé contre un polypeptide selon l'une quelconque des revendications 1 à 3.
12. Composition pharmaceutique contenant un polypeptide selon l'une quelconque des revendications 1 à 3 ou un anticorps selon la revendication 11 en association avec un diluant ou un support pharmaceutiquement acceptable.

*Figure 1*

**Figure 2**



**Figure 3**

*Figure 4*

hIL-2R(Tac)






Figure 5



pcDL-SRα-hG-CSF-hTac(Δ leader) (pSGT)


pcDL-SRα-hRARα-hTac(Δ leader) (pSRT)

BEST AVAILABLE COPY


*Figure 6*





*Figure 7*



*Figure 8*



**Figure 9**

*Figure 10*

*Figure 11*

